Gilead Sciences Inc.

4 de set. de 2026, 20:08 UTC

Gilead Sciences shares are lower today, reflecting broader market trends. Zacks raised Q1 2027 earnings estimate to $2.09 per share.

3 de set. de 2026, 20:07 UTC

Gilead Sciences shares are higher, reflecting broader market gains. The stock remains above its 20-day moving average, supporting positive sentiment in biotechnology.

2 de set. de 2026, 23:16 UTC

Gilead Sciences shares are lower in after-market hours, reflecting a decline throughout the trading day amid a weaker-than-expected ADP payrolls report.

1 de set. de 2026, 23:06 UTC

Gilead Sciences shares are trading higher in after-market hours, reflecting a gain since Tuesday's close, amid broader market movements influenced by rising oil prices.

31 de ago. de 2026, 22:26 UTC

Gilead Sciences shares are higher in after-market trading, positioned above the 20-day moving average and near the upper end of their one-month range.

28 de ago. de 2026, 23:46 UTC

Gilead Sciences, Inc. shares are trading higher during after-market hours, maintaining a position above the 20-day moving average. No specific news was identified.

27 de ago. de 2026, 23:01 UTC

Gilead Sciences received FDA approval for Bixlenvo, the first single-tablet regimen for HIV. Shares advanced in after-market trading, reflecting investor optimism.

26 de ago. de 2026, 23:01 UTC

Gilead Sciences, Inc. shares are trading lower in after-market hours following a volatile session, despite being above the 20-day moving average.

25 de ago. de 2026, 19:36 UTC

Gilead Sciences gains retail interest after European approval of Trodelvy. The company raised its 2026 sales guidance to $30.1 billion to $30.4 billion.

24 de ago. de 2026, 23:06 UTC

Gilead Sciences gains after European approval for Trodelvy and raises 2026 sales guidance to $30.1–$30.4 billion, reflecting strong performance in HIV and oncology.

21 de ago. de 2026, 20:06 UTC

Gilead Sciences Inc's shares are higher, maintaining upward momentum since Thursday, despite a slight pullback earlier in the session. The stock remains above its 20-day moving average.

20 de ago. de 2026, 23:36 UTC

Gilead Sciences Inc shares are higher in after-market trading. Strong broader market performance and declining initial jobless claims support this positive momentum.

19 de ago. de 2026, 20:02 UTC

Gilead Sciences awarded its U.S. media account to Publicis, shifting from Interpublic. Shares are advancing amid positive investor sentiment and social media discussions.

18 de ago. de 2026, 20:02 UTC

Gilead Sciences shares are higher, trading above $138 amid positive sentiment. Analysts see potential for targets between $140 and $145 with strong support levels.

17 de ago. de 2026, 20:06 UTC

Gilead Sciences shares are advancing, navigating a resistance area and remaining above the 20-day moving average, reflecting continued trader interest.

14 de ago. de 2026, 19:26 UTC

A federal appeals court upheld an injunction against Gilead's HIV medications. Shares reached a four-week high of $138.33, remaining roughly flat since Thursday.

13 de ago. de 2026, 23:11 UTC

Gilead Sciences shares are lower in after-market trading, reflecting routine activity amid broader economic data showing rising jobless claims and steady producer prices.

12 de ago. de 2026, 20:06 UTC

Gilead Sciences announced a collaboration with Nucleai for AI-driven biomarker discovery. Shares are trading lower despite the partnership announcement.

11 de ago. de 2026, 20:06 UTC

Gilead Sciences reported second-quarter revenue of $7.80 billion, exceeding estimates. Shares are higher since Monday, reflecting positive sentiment after the earnings report.

10 de ago. de 2026, 23:06 UTC

Gilead Sciences Inc. shares are higher in after-market hours, reflecting stability with routine trading and no specific news identified.

7 de ago. de 2026, 20:06 UTC

Gilead Sciences reports $65 million in revenue from Kymera Therapeutics collaboration, including a $45 million option exercise fee. Shares are higher despite earlier session pullback.

6 de ago. de 2026, 23:02 UTC

Gilead Sciences filed a mixed securities shelf, raising investor concerns about share dilution. Shares are trading lower in after-market hours.

5 de ago. de 2026, 19:53 UTC

Gilead Sciences shares are lower after reporting a $10.50 billion net loss and revising fiscal 2026 earnings guidance downward, despite strong HIV sales.

4 de ago. de 2026, 23:02 UTC

Gilead Sciences reports a $10.50 billion net loss for Q2, lowering full-year GAAP EPS guidance. Shares are trading lower in after-market hours.

3 de ago. de 2026, 19:51 UTC

Gilead Sciences advances following a California Supreme Court ruling on HIV drug innovation, boosting investor sentiment ahead of Q2 earnings report.

31 de jul. de 2026, 23:16 UTC

Gilead Sciences shares are higher in after-market trading amid market fluctuations. Accessibility challenges for lenacapavir in Latin America may impact potential sales.

30 de jul. de 2026, 21:31 UTC

Gilead Sciences shares are lower in after-market hours, continuing a decline since Thursday's close and remaining below the 20-day moving average.

29 de jul. de 2026, 22:41 UTC

Gilead Sciences Inc shares are lower in after-market trading, with no specific news identified to explain the decline amid notable volatility earlier in the session.

28 de jul. de 2026, 23:01 UTC

Gilead Sciences received endorsement for Trodelvy with Keytruda for specific breast cancer patients, boosting shares modestly higher in after-market trading.

27 de jul. de 2026, 18:07 UTC

Morgan Stanley maintains Overweight rating on Gilead Sciences, lowering price target to $165. Shares are higher since Friday, supported by positive news on Trodelvy.